Global Pharmacogenomic Testing Service Market to Register Stunning Growth at a CAGR of ~12% by 2034 | DelveInsight

DelveInsight projects the global pharmacogenomic testing services market will grow from $8.1B (2025) to $22.4B by 2034, implying ~12% CAGR over 2026–2034. Growth is attributed to adoption of personalized/precision medicine, increased use in oncology/psychiatry/cardiology, and advances in NGS and other genomic technologies, supported by regulatory and reimbursement tailwinds. Multiple product launches and expanded test offerings (e.g., FoundationOne® PGx; Labcorp DPYD expansion; Quest PGx offering) reinforce accelerating commercial uptake.

Analysis

This is more of a channel-expansion signal than a clean earnings catalyst. The near-term winners are the large diagnostic labs with existing physician relationships and payer contracting power — they can add PGx as another ordered item, but the economics are likely to be incremental rather than transformative because many tests will be bundled into broader panels and reimbursed conservatively. That favors LAB and DGX over smaller single-product platforms, which may see adoption but not enough scale to offset pricing pressure.

The bigger second-order effect is competitive compression: if PGx becomes a routine workflow item, standalone specialists lose pricing power as large labs absorb the menu item and cross-sell through oncology, psych, and cardiology channels. The market is likely overestimating benefit to sequencing/tool vendors like ILMN and TMO, because much of PGx volume is assay-light and PCR/microarray-based; volume growth does not automatically translate into high-margin consumables growth. For pharma, the structural win is lower trial-and-error prescribing, but that monetizes slowly and depends on guideline inclusion.

Catalyst timing matters: over the next 1-3 months, this is mostly sentiment and channel-check fodder, not a hard revenue event. The real inflection requires payer coverage expansion, EHR order-set integration, and society guideline updates over 6-18 months; absent those, the forecasted growth rate is more aspirational than tradable. The contrarian read is that the market may be underappreciating reimbursement friction and physician inertia — if reactive testing remains the dominant mix, the addressable market grows but the public-company capture stays modest.

Key Decisions for Investors

• Long LAB vs. short MYGN over 3-6 months: express the view that diversified lab distribution and reimbursement infrastructure will capture more incremental PGx volume than a narrower standalone franchise. Target 1.5-2.0x relative upside if menu expansion starts showing up in ordered-tests data; thesis fails if MYGN posts accelerating payer-covered volume or LAB margin compresses from discounting.
• Watchlist, not immediate trade: add DGX on weakness only if management commentary shows PGx attach rates rising without adverse reimbursement pressure. This is a lower-beta way to own the theme; upside is modest but durable, while downside is limited unless guideline adoption stalls or pricing weakens.
• Avoid chasing ILMN/TMO on this headline. Treat any rally in the tools names as fadeable unless there is evidence that PGx is shifting to NGS-heavy workflows; absent that, the revenue capture is likely too small to matter versus current valuations.
• Set a catalyst alert on CMS/payer coverage and oncology guideline updates over the next 6-12 months. If coverage broadens or DPYD-like tests become standard-of-care in more indications, re-rate LAB/DGX higher; if coverage remains fragmented, expect the trade to fade.